Amerise Biosciences Financial Statements
Amerise Biosciences financial statements. In FYNone, Amerise Biosciences (AMERISE) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 10.0% and ROE of 20.0%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Amerise Biosciences stock price NSE.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
AMERISE Revenue, Net Profit & EBITDA — Year-on-Year Growth
AMERISE YoY (March 2026 vs Period). Analyse AMERISE promoter holding to track promoter, FII and institutional holdings.
AMERISE Income Statement — Revenue, EBITDA & Net Profit
Amerise Biosciences revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 10.0%. Read AMERISE dividend growth for the complete payout history and dividend yield track record.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Operating Profit Margin % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Earnings Per Share (₹) | 0.00 | 0.00 | 0.00 | -0.02 | -0.02 | 0.08 | -0.05 | -0.02 | 0.00 | 0.00 | -0.14 | 0.00 | -0.01 |
AMERISE Balance Sheet — Assets, Liabilities & Shareholders' Equity
AMERISE total assets ₹7 Cr, total equity ₹5 Cr, total liabilities ₹ Cr (2026) — ROE 20.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 7 | 9 | 5 | 6 | 12 | 6 | 6 | 6 | 6 | 6 | 7 | 7 |
| Current Assets | ||||||||||||
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 2 | 2 | 5 | 5 | 3 | 5 | 1 | 2 | 2 | 0 | 3 |
| Other Assets | 4 | 6 | 3 | 1 | 7 | 3 | 1 | 5 | 3 | 3 | 7 | 4 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 5 | 5 | 5 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 7 | 7 |
| Share Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves & Surplus | -1 | -1 | -1 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | 0 | 0 |
AMERISE Cash Flow Statement — Operating, Investing & Financing
Amerise Biosciences operating cash flow ₹-1 Cr, investing ₹2 Cr, financing ₹0 Cr, net cash flow ₹1 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | 3 | 0 | 0 | 0 | 0 | 5 | -2 | 0 | -4 | 1 | 0 |
| Investing Activities | 2 | -3 | 0 | 0 | 0 | 0 | -5 | 2 | 0 | 4 | -1 | 0 |
| Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |